NEW YORK — Australian biotech firm Microba said today that it has partnered with Macrogen subsidiary Psomagen to introduce a microbiome analysis test in the US.
Microba recently launched a direct-to-consumer service in Australia called Insight, which uses shotgun metagenomics to analyze customers' gut microbiomes and generate a personalized report. Under the terms of the deal, Psomagen will introduce a microbiome test based on Microba's technologies in the US before the end of the year.
Additional terms were not disclosed.
The partnership represents the latest step in an ongoing alliance between Microba and Rockville, Maryland-based Psomagen, a recently renamed subsidiary of South Korea's Macrogen. In March, Microba began working with Macrogen to develop microbiome research services for international markets. A few months later, Macrogen made a $2.8 million investment in Microba.